Carthera’s SonoCloud demonstrates potential in Alzheimer’s patients
pharmafile | March 30, 2022 | News story | Business Services |
Carthera has announced the publication of results in the Alzheimer’s Research & Therapy Journal, from an investigator-sponsored trial evaluating the trail evaluating the safety and efficacy of the use of SonoCloud technology in patients with mild Alzheimer’s Disease (AD).
SonoCloud is an innovative ultrasound-based medical device used to treat a wide range of brain diseases. It is an implantable 1 MHz ultrasound device that can be activated on demand using a transdermal needle connected to an external interface, harnesses the therapeutic potential of this technique in an easy-to-use system that allows for repeated treatments in patients.
The trial, conducted by ‘Assistance Publique Hopitaux de Paris (AP-HP)’ showed that the SonoCloud can disrupt the BBB in Alzheimer’s patients, and further confirmed the safety previously demonstrated in patients with brain tumours, published in 2019 in Clinical Cancer Research.
Pr Alexandre Carpentier, commented: “The study’s findings complement the promising results already published and confirm the significant role that the SonoCloud device can play in the treatment of a wide spectrum of brain diseases, particularly if coupled with a novel drug therapy. Carthera is actively seeking collaborations with pharma partners to further develop this technique and allow a greater number of patients to benefit from this innovative treatment.”
“We’re currently planning a clinical trial that will lead to marketing authorisation of the SonoCloud for the treatment of glioblastoma while also continuing to explore this technology in a greater number of brain indications in combination with various therapeutic agents,” added Frédéric Sottilini, CEO of Carthera. “The outcomes of this study reinforce our conviction that the SonoCloud has the potential to unlock the efficacy of therapies for brain diseases that were previously untreatable.”
Lina Adams
